Taken together, these results show that myelin peptide-specific T cell responses can be readily screened and monitored in PBMC from MS patients with diverse HLA-DRB1 genotypes, as a possible selection criterion for peptide-specific immunotherapy. The gene discussed is HLA-DRB1; the disease is myeloid sarcoma.